RESEARCH USE AND EDUCATIONAL DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
Melanotan I, also known as afamelanotide, has been investigated in pigmentation research and in clinical studies of particular skin-related conditions. The evidence ranges from small experiments measuring melanin to larger trials of a pharmaceutical implant in erythropoietic protoporphyria, or EPP. Research has also examined afamelanotide alongside light therapy for vitiligo. These are different research settings, not interchangeable demonstrations of general tanning safety. This article reviews three published studies and explains why the tested formulation and study population matter. [1–3]
WHAT IS MELANOTAN I?
Melanotan I is a synthetic analogue of alpha-melanocyte-stimulating hormone, commonly shortened to alpha-MSH. Its research history concerns signaling involved in pigmentation. The name afamelanotide appears in clinical literature, particularly studies using a controlled-release implant. Identifying the molecule is only the first step in interpreting that literature: a clinical implant and a laboratory research material are not equivalent simply because their labels refer to the same compound. [1,2]
EARLY RESEARCH MEASURED CHANGES IN MELANIN
A 2000 study by Dorr and colleagues examined seven volunteers and reported increased eumelanin, a dark form of skin pigment, following Melanotan I exposure. The investigators used objective measurements, including skin sampling in a subset, rather than relying only on visual impressions. Pheomelanin, a different pigment, did not show a statistically significant change in the reported analysis. [1]
This small study helped characterize a biological response. It was not designed to show that darker skin prevents cancer or makes ultraviolet exposure harmless. Measuring pigment production answers a narrower question than measuring long-term health outcomes. The limited number of participants also restricts what can be learned about uncommon adverse effects or variation across skin types.
AFAMELANOTIDE IN ERYTHROPOIETIC PROTOPORPHYRIA
EPP is a condition associated with painful reactions to light. In 2015, Langendonk and colleagues reported two randomized, placebo-controlled trials involving 168 enrolled participants across European and US studies. The pharmaceutical afamelanotide implant was associated with greater pain-free sunlight exposure and improved quality-of-life measures. Adverse events were generally mild; pigment changes, including darkening around implant sites and existing moles, were among the observations. [2]
The trials used different follow-up periods and definitions of sunlight exposure, so their numerical results should not be casually pooled. More fundamentally, relief of light-triggered symptoms in EPP is a specific clinical question. It does not establish the safety of cosmetic tanning, intentional ultraviolet exposure or a separately sourced research preparation.
VITILIGO RESEARCH USED COMBINATION TREATMENT
A randomized study published in 2015 investigated 55 people with nonsegmental vitiligo. Participants received narrowband UV-B phototherapy either alone or together with an afamelanotide implant. At day 168, reported repigmentation was approximately 48.6% in the combination group and 33.3% with phototherapy alone. Some body regions showed earlier responses with the combination. [3]
This finding concerns an addition to phototherapy, not proof that afamelanotide alone produces the same effect. The trial was relatively small and included selected skin phototypes. Erythema occurred in both groups, while nausea and minor infections were also reported in the combination group. The study therefore needs to be described with its treatment context and adverse-event observations intact. [3]
WHAT THESE STUDIES DO NOT ESTABLISH
The evidence supports distinct statements about pigment biology, a specific EPP implant program and an investigational combination in vitiligo. It does not justify treating every Melanotan I material as a clinically validated product. Nor does an increase in pigment demonstrate prevention of skin cancer, elimination of ultraviolet damage or universal safety.
For research interpretation, the practical questions are which material was tested, how outcomes were measured, who participated and how long they were followed. Keeping those details attached to the findings produces a more useful account than describing the compound as simply a tanning or photoprotection peptide.
REFERENCES
1. Dorr RT, Dvorakova K, Brooks C, et al. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochemistry and Photobiology. 2000;72:526–532.
https://pubmed.ncbi.nlm.nih.gov/11045725/
2. Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for Erythropoietic Protoporphyria. New England Journal of Medicine. 2015;373:48–59.
https://doi.org/10.1056/NEJMoa1411481
3. Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatology. 2015;151:42–50.
https://doi.org/10.1001/jamadermatol.2014.1875